Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Metronidazole Tablets USP, 250 mg and 500 mg. The product received approval in 17 months under the new GDUFA regime. The product is ready for immediate launch. Metronidazole Tablets are indicated for treatment of wide variety of infections caused by particular types of bacteria and parasites.
According to IMS data, the US market for Metronidazole Tablets USP, 250 mg and 500 mg is approximately $50 million. The product will be manufactured at the company’s oral dosage facility at Bangalore and marketed by Strides in the US Market.
Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and and semi-solids.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: